Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Losk, Scott
RETHINK-1, NCT04994483: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease	Active, not recruiting	3	750	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	10/24	10/24
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD	Completed	2/3	320	US	Buntanetap/Posiphen, Posiphen Tartrate, Placebo	Annovis Bio Inc.	Alzheimer Disease	02/24	02/24
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Active, not recruiting	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	08/24
COG1201, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies	Active, not recruiting	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia With Lewy Bodies	11/24	11/24
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease	Recruiting	2	282	Europe, Canada, US, RoW	GSK4527226, Placebo	GlaxoSmithKline, Alector Inc.	Alzheimer's Disease	12/26	05/29
Andersen, Tawnya
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Active, not recruiting	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	08/24
Tawnya
No trials found